Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias

NCT02041325 is registered in ClinicalTrials.gov with Boston VA Research Institute, Inc. as lead sponsor.

NCT NCT02041325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02041325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias
Lead sponsor
Boston VA Research Institute, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
April 30, 2014
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell disorder